

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Keymed Biosciences Inc.
康諾亞生物醫藥科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2162)

INSIDE INFORMATION ANNOUNCEMENT

(1) UPDATE ON PRODUCT REVENUE FOR THE FIRST HALF OF 2026 AND (2) POSITIVE PROFIT ALERT

This announcement is made by Keymed Biosciences Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) is pleased to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that:

(1) UPDATE ON PRODUCT REVENUE FOR THE FIRST HALF OF 2026

During the first half of 2026, revenue generated from the Company’s product Kangyueda® (康悦達®) (IL-4Rα monoclonal antibody, Stapokibart) exceeded RMB390 million, representing a year-on-year increase of more than 132%. Since January 1, 2026, all three approved indications of Kangyueda®, namely moderate-to-severe Atopic Dermatitis (AD) in adults, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and Seasonal Allergic Rhinitis (SAR), as well as its two packaging formats of vial and pre-filled autoinjector, have been included in China’s National Reimbursement Drug List, with a medical insurance payment standard of RMB1,039 per unit for the 300 mg/2 mL specification, significantly enhancing the affordability and accessibility of the product for patients in China. As of June 30, 2026, the commercialization team of the Company had grown to more than 500 members and covered more than 1,600 hospitals in over 260 cities, with market access initiatives progressing rapidly.

In addition, in January and March 2026, the marketing applications for Stapokibart for the treatment of moderate-to-severe AD in adolescents and Prurigo Nodularis (PN) were accepted by the National Medical Product Administration of the PRC, respectively.

The strong performance of Kangyueda® during the first half of 2026 validated its market potential, further strengthened the Company's confidence in commercialization and provided the Company with stable cash flow. Meanwhile, the Company continued to advance global innovation. Progress in multiple business development initiatives validated the innovation potential of the Company's platform and the results of its diversified licensing collaborations, creating sustained growth potential for the Company's value. The Company and its partners are rapidly advancing multiple clinical studies involving pipeline candidates including CMG901 (Claudin18.2 ADC), CM336 (BCMA/CD3 bispecific antibody) and CM512 (TSLP×IL13 bispecific antibody), while continuing to increase investment in early-stage innovation in areas including the central nervous system (CNS).

(2) POSITIVE PROFIT ALERT

Based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2026 (the “**Reporting Period**”) and the information currently available to the Board, the Group is expected to record a profit of not less than RMB1.2 billion for the Reporting Period, as compared with a loss of approximately RMB79 million for the corresponding period of the previous year.

The Group's turnaround from loss to profit during the Reporting Period was mainly attributable to the following:

- ① In connection with the previous disposal of the Group's minority equity interest in Ouro Medicines (references are made to the announcements of the Company dated March 24, 2026 and April 15, 2026), the Group received an upfront payment in an aggregate amount equivalent to US\$257 million during the second quarter of 2026 (reference is made to the announcement of the Company dated June 5, 2026). Such upfront payment was recognized as other income during the Reporting Period, amounting to approximately RMB1.68 billion.
- ② KYM Biosciences Inc. (“**KYM**”), a non-wholly owned subsidiary in which the Group holds a 70% equity interest, previously entered into a license agreement with AstraZeneca in relation to CMG901 (Claudin 18.2 ADC) (reference is made to the announcement of the Company dated February 23, 2023). During the first quarter of 2026, AstraZeneca announced that it had initiated a multi-center, randomized, controlled Phase III clinical study of CMG901 (AZD0901) in combination with capecitabine, with or without rilvegostomig, as a first-line treatment for Claudin 18.2-positive, HER2-negative advanced/metastatic gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma (CLARITY-Gastric 02), and completed the dosing of the first subject, thereby triggering milestone payments in an aggregate amount of US\$45 million. During the first quarter of 2026, the Group received milestone payment in an aggregate amount equivalent to US\$31.5 million (reference is made to the announcement of the Company dated March 10, 2026). Such milestone payment was recognized as collaboration income during the Reporting Period, amounting to approximately RMB220 million.

- ③ Leveraging its outstanding clinical value, the Company's innovative product Kangyueda® continued to reach an increasing number of patients. It recorded sales revenue of RMB390 million during the first half of 2026, representing a year-on-year increase of 132%, and provided the Company with continued revenue.

The Group continued to optimize its scientific and efficient expense management capabilities. While accelerating the research and development of innovative products and the advancement of its pipelines, the Group also achieved results in cost control.

The financial information contained in this announcement has been prepared based on the internal management records of the Group and has not been audited or reviewed by the external auditor. Accordingly, such information is provided for investors' reference only. Due to various uncertainties arising in the process of collecting and compiling such information, it may differ from the information to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company, including but not limited to information contained in annual or interim disclosures.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Keymed Biosciences Inc.
Dr. Bo CHEN
Chairman

Hong Kong, July 15, 2026

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Bo CHEN, Dr. Changyu WANG and Dr. Gang XU as executive Directors; Mr. Qi CHEN, Dr. Min Chuan WANG and Mr. Yilun LIU as non-executive Directors; Prof. Xiao-Fan WANG, Prof. Yang KE and Mr. Cheuk Kin Stephen LAW as independent non-executive Directors.